Amelia Jernigan, MD
Gynecologic Oncology · Cleveland, OHNPI 1275777682
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $58,615 of the $84,679 with a category attached, or 69.2%. AstraZeneca accounts for 79.8% of it on its own, with 37 other manufacturers making up the rest. 2025 is the largest year on record at $22,593, more than ten times the $887 reported in 2019. Among gynecologic oncology clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 207 payments — averaging $409.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$68K
- Merck$12K
- GSK$620
- Eisai Inc.$570
- Meditrina$363
- Johnson & Johnson$324
- plus $3K from 32 others
Across 21 payments — averaging $6986.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$120K
- Immunogen, Inc.$23K
- Merck$3K
What the payments were for
- Consulting fees$10,78813%
- Speaking & faculty fees$58,61569%
- Travel & lodging$7,5169%
- Food & beverage$7,6079%
- Education$1540%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 62 | $67,554 |
| Merck | 38 | $11,855 |
| GSK | 14 | $620 |
| Eisai Inc. | 10 | $570 |
| Meditrina | 2 | $363 |
| Johnson & Johnson(2 entities) | 4 | $324 |
| Intuitive Surgical | 3 | $320 |
| Daiichi Sankyo Inc. | 3 | $318 |
| AbbVie | 9 | $278 |
| Medtronic | 2 | $260 |
| Baxter Healthcare | 4 | $180 |
| Pacira Pharmaceuticals Incorporated | 6 | $164 |
| Immunogen, Inc. | 3 | $162 |
| Biom'up France SAS | 2 | $159 |
| Tesaro, Inc. | 3 | $154 |
| Karyopharm Therapeutics Inc. | 1 | $144 |
| Clovis Oncology, Inc. | 10 | $134 |
| Caris MPI, Inc. | 2 | $125 |
| E.r. Squibb & Sons, L.L.C. | 1 | $121 |
| Gilead | 1 | $121 |
| Genmab U.S., Inc. | 2 | $98 |
| Corcept Therapeutics | 1 | $96 |
| AMAG Pharmaceuticals, Inc. | 1 | $96 |
| Myriad Genetic Laboratories, Inc. | 5 | $79 |
| Bristol Myers Squibb | 2 | $58 |
| Coloplast | 2 | $49 |
| Hologic Sales And Service, LLC | 1 | $47 |
| Novartis | 2 | $40 |
| Tactile Systems Technology Inc | 2 | $30 |
| Dexcom, Inc. | 1 | $27 |
| Dilon Technologies, Inc. | 1 | $27 |
| LSI Solutions Inc | 1 | $18 |
| Mallinckrodt Enterprises LLC | 1 | $17 |
| Lilly USA, LLC | 1 | $17 |
| Aspira Women's Health Inc | 1 | $16 |
| Amgen | 1 | $14 |
| Bayer | 1 | $12 |
| Sanofi | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYNPARZA$66,598
- KEYTRUDA$716
- JEMPERLI$370
- Da Vinci Surgical System$290
- LENVIMA$247
- XPOVIO$144
- Enhertu$123
- Reblozyl$121
- Trodelvy$121
- ZEJULA$121
- Elahere$118
- Signia$116
- ECHELON ENDOPATH$111
- Echelon Flex$111
- HemoBlast Bellows$111
- MI CANCER SEEK$106
How this compares
$84,679 in reported general payments places this provider in the 90th percentile of 62 gynecologic oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZejulaNiraparib Tosylate | 11 | $202,122 |
| LynparzaOlaparib | 11 | $178,471 |
| EliquisApixaban | 17 | $9,687 |
| VeozahFezolinetant | 12 | $6,751 |
| Cyclophosphamide | 13 | $1,204 |
| Ondansetron Hcl | 31 | $836 |
| Letrozole | 19 | $233 |
| Gabapentin | 25 | $170 |
| Olanzapine | 12 | $60 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKZejula | $620 | $202,12211 claims |
| AstraZenecaLynparza | $67,554 | $178,47111 claims |
| Lilly USA, LLCOlanzapine | $17 | $6012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 62 gynecologic oncology providers in Ohio.
Other gynecologic oncology in Cleveland
- Kimberly ResnickCleveland$29K
- Peter RoseCleveland$4K
- Kevin EliasCleveland$4K
- Chad MichenerCleveland$3K
- Mariam Al HilliCleveland$2K
- Robert DebernardoCleveland$2K
- Anthony RizzoCleveland$1K
- Lisa Rauh-BenoitCleveland$930
- Roberto VargasCleveland$482
- Lindsay FergusonCleveland$467
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.